A Study of LY3314814 in Healthy Participants
Study identifier:15993
ClinicalTrials.gov identifier:NCT03222427
EudraCT identifier:2017-001181-18
CTIS identifier:N/A
Study Complete
Official Title
An Absolute Bioavailability Study of LY3314814 in Healthy Subjects Using an Intravenous Tracer Method
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
LY3314814, [13C415N3] LY3314814
Sex
All
Actual Enrollment
8
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 15 Jan 2018
Primary Completion Date: 16 Feb 2018
Study Completion Date: 16 Feb 2018
Study design
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Basic Science
Verification:
Verified 01 Oct 2019 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
Eli Lilly and Company
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: LY3314814 Single 50 milligram (mg) dose of LY3314814 administered orally | Drug: LY3314814 Administered orally |
| Experimental: [13C415N3] LY3314814 Single 100 micrograms (μg) intravenous (IV) dose of [13C415N3] LY3314814 administered as an IV infusion. | Drug: [13C415N3] LY3314814 Administered as an IV infusion |
Contacts
Investigators
Principal Investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
